Industry news that matters to you.  Learn more

Researchers Find That Tumor DNA and Cells in the Blood Can Be Used to Diagnose Prostate Cancer and Drug Resistance in Breast Cancer

Last month, the “Molecular Diagnostics” issue of Clinical Chemistry, the journal of AACC, featured new research on a genetic test for prostate cancer that could replace the unreliable prostate specific antigen (PSA) test, as well as a more accurate test for breast cancer drug resistance. Both tests could help patients receive more targeted treatment for prostate and breast cancer, which in the U.S. are the second leading causes of cancer death in men and women, respectively.

Oncodesign has Entered into a Services Agreement with Eisai to Develop a New Personalized Medicine Program in Earlier Line Metastatic Breast Cancer Treatment

ONCODESIGN (FR0011766229 – ALONC), a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment, recently announced the signing of an agreement with Eisai Inc. Oncodesign will conduct in vivo pharmacology studies and Eisai will provide gene expression profiling analysis using Oncodesign’s patient-derived xenograft models (PDX) to investigate the potential of eribulin mesylate (“eribulin”) in earlier line treatment of metastatic breast cancer.

Oncotype DX DCIS Score Represents Breakthrough in Personalizing Treatment of Pre-Invasive Breast Cancer

Genomic Health, Inc. (Nasdaq: GHDX) recently announced positive results from the second large clinical validation study of Oncotype DX® in patients with a pre-invasive form of breast cancer known as DCIS (ductal carcinoma in situ). The study, conducted by the Ontario DCIS Study Group of Sunnybrook Health Sciences Centre in Canada, reconfirmed that the Oncotype DX DCIS Score™ is a strong predictor of local recurrence, which could be either invasive breast cancer or DCIS (p<0.001).

Quest Diagnostics Introduces BRCAvantage Plus, Providing New Choices in Genetic Breast Cancer Risk Testing

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, recently announced BRCAvantage Plus, the company’s first suite of lab-developed test services for assessing genetic breast cancer risk based on clinically validated non-BRCA as well as BRCA genes. The new service is now available in all 50 states.

bioTheranostics’ Breast Cancer Index Genomic Test Selected as Finalist in 27th Annual CONNECT Most Innovative New Product Awards

bioTheranostics, Inc., a leading genomic solutions provider for cancer, recently announced that its Breast Cancer Index molecular test has been selected as a finalist in the Life Sciences—Diagnostics & Research Tools category for the 2014 Most Innovative New Product Awards, sponsored by CONNECT. CONNECT, a regional program that catalyzes the creation of innovative technology and life sciences products in San Diego County, continues its 27-year tradition of honoring San Diego’s leaders of innovation and groundbreaking new products with the annual award.